SAN DIEGO--(BUSINESS WIRE)--SynteractHCR, a full-service, international contract research organization (CRO), will exhibit at several events this spring: Outsourcing in Clinical Trials Europe in Dusseldorf, Germany; Outsourcing in Clinical Trials East Coast in King of Prussia, PA; German ePharma Day in Munich, and the DIA 2015 Annual Meeting in Washington, DC. These conferences, which are set up to connect members of the biopharma and life sciences communities, allow SynteractHCR experts to share clinical trial expertise and best practice information through exhibits, networking, and/or speaking engagements.
At OCT Europe, May 19-20, 2015, SynteractHCR will exhibit in booth #61. On Tuesday, May 19 at 10:30 a.m., Dr. Martine Dehlinger-Kremer, global vice president, medical and regulatory affairs, will present, “Evaluating the New EU Clinical Trials Regulation: News and Challenges.” Her presentation will address the timeline and advantages expected as well as core aspects of the regulation and country-specific differences that sponsors will need to know. Dr. Dehlinger-Kremer has nearly 25 years of regulatory affairs leadership experience and has been a strong advocate for common standards in the industry. She will also present on this topic’s challenges from the regulatory point of view during German ePharma Day, June 11th, in Munich. In addition, she will host a Webinar on this topic July 23rd, for those who may not be able to attend either presentation.
From May 27-28, SynteractHCR will exhibit in booth #44 at OCT East Coast and will welcome attendees to hear a presentation on May 27th at 2:15 p.m. from Barbara Ruby, project director, on “Recruitment and Retention for Orphan Disease Studies – A Patient’s Perspective.” She will cover strategic patient recruitment ideas, inclusion and exclusion criteria, maintaining connection with patient groups and reporting, as well as the level of support that sponsors should expect during a study. Ruby has more than 20 years of experience in clinical research, including more than ten years as a project manager. At SynteractHCR, she manages cross-functional teams and is responsible for ensuring that all project deliverables are completed on time. As an expert in managing orphan disease studies, she will share the best practices that make these challenging studies successful.
The Drug Information Association’s 51st Annual Meeting will be held from June 14-18 at the Walter E. Washington Convention Center, where SynteractHCR will exhibit in booth #1335. An anticipated 7,000+ attendees come to this largest multidisciplinary event that brings together a global network of life sciences professionals to foster innovation that leads to the development of safe and effective medical products and therapies for patients. SynteractHCR, focused on its company philosophy of “Shared Work. Shared Vision. Tomorrow’s Treatments,” will identify how its way of doing business supports sponsors to efficiently bring their innovative drugs and therapies to market, to patients who need them.
Attendees who might like to schedule an appointment with SynteractHCR can contact Matt Smith, SVP Commercial Operations, at 760-268-8200 or Matt.Smith@synteracthcr.com. For a full list of SynteractHCR's events, please see its schedule of events online, or follow its social media channels on LinkedIn and Twitter.
About SynteractHCR (www.synteracthcr.com)
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 50 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.